

KDIGO Form* for Disclosure of Potential Competing Interests

1. INSTRUCTIONS

This form will provide the public with information about your other interests that could influence how they perceive your work for KDIGO. All KDIGO volunteers should submit a form and vouch for its accuracy. This is part of the KDIGO commitment to total transparency in all its activities.

2. IDENTIFYING INFORMATION

1. Given Name (First Name): Joachim

2. Surname (Last Name): Ix

3. Date: March 12, 2023

4. Title and Organization/Affiliation: Professor of Medicine / University of California San Diego

3. RELEVANT ACTIVITIES

This section asks about your financial relationships with industry, non-government, and government bodies and non-financial interests that may give the appearance of potentially influencing your work with KDIGO. You should disclose interactions with any entity that might be considered broadly related to the work being conducted for KDIGO or for the topic under consideration (e.g., the topic of the guideline for which you will be a Work Group member).

Report all sources of revenue paid (or promised to be paid) directly to you or to your institution on your behalf over the last 24 months.

Regarding non-financial interests, it is expected that you will have previous activities that are conceptually linked to your work with KDIGO.

Place an "x" in the appropriate boxes to indicate whether you have financial relationships with entities (>€500) or non-financial interests as described in the instructions. You should report relationships that were present during the last 24 months or that you expect within the next 12 months. Complete each question by selecting "None" or providing the requested information. For examples of the various types of interest, please see Appendix A. Examples of

competing interests and management. All questions refer to your work with KDIGO or the topic under consideration related to your work with KDIGO.

Financial disclosures of interest							
		Name all entities with whom you have this relationship or indicate none (add rows as needed)					Comments
1	Support for any study or manuscript pertaining to the topic of interest (e.g., funding, provision of study materials,	⊠ None		,			
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest	
	medical writing,						
	article processing charges)						
2	Grants or contracts from any entity (if not indicated in item #1 above) related to the	□ None					
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest	
	topic of interest	NIDDK		\boxtimes			
		NHLBI		\boxtimes			
		Baxter		\boxtimes			
		Juv. Diabetes Research Foundation					
3	Royalties or licenses	⊠ None					
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest	
4	Consulting fees	□ None					
		Entity	Paid to you	Paid to	Relevant to	Not	

				institution	topic of interest	relevant to topic of	
					meresi	interest	
		Bayer	\boxtimes				
		Cincor	\boxtimes				
5	Payment or honoraria for	⊠ None					
	lectures, presentations, speakers' bureaus,	Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest	
	manuscript						
	writing or educational						
	events						
6	Payment for expert	⊠ None					
	testimony	Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest	
7	Funding for travel and/or	□ None					
	accommodation	Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest	
		KDIGO	\boxtimes				
8	Patents planned,	⊠ None					
	issued, or pending	Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☐ None					
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest	
		Sanifit	\boxtimes				
		NHLBI	\boxtimes				

10	Any <i>paid</i> leadership or						
fiduciary role in other board,		Entity			Paid to you	Paid to institution	
	society,						
	committee, or advocacy						
	group relevant						
	to the topic of interest						
11	Stock or stock options	⊠ None					
		Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest	
12	Receipt of equipment,	□ None					
	materials, drugs, medical writing, gifts, or other services	Entity	Paid to you	Paid to institution	Relevant to topic of interest	Not relevant to topic of interest	
		Genentech		\boxtimes			
13	Other <i>financial</i>	⊠ None					
	interests relevant to the	Fari.			Daidta	Daidta	
	topic of interest	Entity Paid to you Paid to institution					
No	n-financial c						
		Other relationships, activities, or publications that a reasonable person might perceive as potentially influencing your work with KDIGO. Unsupported research publications on a given drug or condition, membership of governmental, non-governmental, advocacy, or lobbying organization, and serving as an expert witness are all examples of non-financial interests that should be disclosed; other examples exist. Please see Appendix A. Examples of competing interests and management for more details.					
1	Any <i>unpaid</i>	⊠ None					
	leadership or						
	fiduciary role in	AlphaYoung					
	other board, society,						
	committee, or	L					

	advocacy group relevant to the topic of interest		
2	Other <u>non-financial</u> interests relevant to the topic of interest	□ None □ Yes If yes, please describe	

Appendix A. Examples of competing interests and management

Example 1: Personal financial, Specific:

Consultancy fee received by a Work Group member from the company producing a product in the class of therapies under consideration, or a product in the comparator class

Action required: Depends on the nature of the consultancy undertaken and the details of the guideline. In general, KDIGO does not recommend specific products in their guideline statements, but rather provides class-based statements.

- Complete exclusion if the interest relates specifically to a product under consideration, or its comparator. The interest is a specific, personal, financial interest.
- Declare and remain if the consultancy is unrelated to a specific product under consideration for the guideline or its comparator. The interest is not specific.

If the consultancy income from the manufacturer of a specific product under review (or a relevant comparator) accounts for a large proportion of the person's income then it would be appropriate to exclude the person from the decision-making.

Example 2: Personal non-financial, Specific

A member of the Work Group for the guideline on condition A has published several papers supporting the use of drug X as first line management of condition A, including a randomized trial and two review articles. The WG is now discussing treatment options for condition A.

Action required: Potential exclusion – this is non-financial, personal, and professional interest and the response will depend on the nature of the view expressed and the risk to perceived objectivity. In determining the level of involvement, the Guideline Chair(s) should consider the balance between this risk and the benefit of the member's input to the Guideline Work Group. In this example, the WG member might derive considerable professional benefit if drug A were recommended as the first-choice treatment in KDIGO guidance on condition A. Therefore, this interest may compromise the member's objectivity (or perceived objectivity) and exclusion may be most appropriate. Open declaration or partial exclusion (i.e., the member to remain in the room to answer questions but not take part in decision-making) will often be sufficient.

In contrast, a WG member who wrote a review article on condition X might not necessarily have a relevant non-financial interest, unless the article took an unusually strong position on drug A or an alternative

Example 3: Non-personal financial, Specific

Grant income received by the Work Group member's employer from the company that manufactures the product.

Action required: Declare and remain – this is a non-personal, financial interest. Because the income goes to the employer, there is no strong conceptual link between this publication and potential benefit to the WG member, regardless of what the guideline recommends. Therefore, there is no realistic threat to objectivity.

Example 4: Personal financial, Non-specific:

Consultancy fees received by a Work Group member from a company with a product unrelated to the guideline

Action required: Declare and remain – there is no strong conceptual link between this publication and potential benefit to the WG member, regardless of what the guideline recommends. Therefore, there is no realistic threat to objectivity.

Example 5: Personal non-financial, Non-specific

Research publications covering epidemiology of condition X, for a WG member on a guideline panel for condition X, where condition X is a complication of CKD.

Action required: Declare above and remain –there is no strong conceptual link between this publication and potential benefit to the WG member, regardless of what the guideline recommends. Therefore, there is no realistic threat to objectivity. If the publications were further removed from the guideline topic (e.g., the member had published extensively on the epidemiology of CKD, but not on condition X specifically) then disclosure would not be required.

Example 6: Non-personal financial, Non-specific

The member's institution or organization receives government funding for evidence reviews not related to the guideline topic.

Action required: These interests typically do not require disclosure except under exceptional circumstances. Again, the test is whether the interest could be perceived as compromising the integrity of the guideline. For example, if a government had a strongly stated policy position that was relevant to a guideline, and if contravening that position could conceivably lead to withdrawal of funding from the member's institution, then in theory this interest might require disclosure and management. In practice, such circumstances are unlikely to occur.